Rob Davis, Merck CEO

Up­dat­ed: Mer­ck look­ing at Seagen takeover bid in the wake of Clay Sie­gal­l's res­ig­na­tion — re­port

Mer­ck is eval­u­at­ing a po­ten­tial buy­out of em­bat­tled Seat­tle biotech Seagen, ac­cord­ing to a re­port from the Wall Street Jour­nal on Fri­day morn­ing.

This is the newest de­vel­op­ment for the biotech af­ter for­mer CEO Clay Sie­gall stepped down from the com­pa­ny — while al­so for­feit­ing his board po­si­tions at oth­er com­pa­nies such as Umo­ja Bio­phar­ma — fol­low­ing al­le­ga­tions of do­mes­tic vi­o­lence that sur­faced last month. He was ini­tial­ly ar­rest­ed in the ear­ly hours of April 23 af­ter a phys­i­cal al­ter­ca­tion with his wife left her with mul­ti­ple bruis­es, ac­cord­ing to a po­lice re­port. Sie­gall has de­nied the al­le­ga­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.